Clinical Trials Logo

WHIM Syndrome clinical trials

View clinical trials related to WHIM Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03005327 Completed - WHIM Syndrome Clinical Trials

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in an Extension Phase, if regionally applicable, until it becomes commercially available or until the study is terminated by the Sponsor.